Antibe Therapeutics Inc. Antibe Therapeutics Inc.

Antibe Therapeutics Inc.

ATE

Classement en actions #31789
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Prix de l'action
$0.21483059
Dernière synchronisation: 2024-05-07
Capitalisation boursière
$11.13M
Changement (1 jour)
0.34%
Changement (1 an)
-0.36%
Pays
CA
Échange Antibe Therapeutics Inc. (ATE)

Catégorie

Healthcare
Historique du prix de l'action pour Antibe Therapeutics Inc. (ATE)
Prix de clôture le plus élevé : $0.22 le 2025-04-01

Prix de clôture le plus bas : $4.78 le 2014-10-01
Historique du prix de l'action de Antibe Therapeutics Inc. de 2014 à 2026
Performance annuelle du prix de l'action
Année Performance
2025 -0.02%
2024 -64.79%
2023 73.56%
2022 -33.35%
2021 -82.11%
2020 -6.13%
2019 60.42%
2018 70.25%
2017 -45.71%
2016 86.85%
2015 -71.73%
2014 0.00%
Prix de l'action pour des entreprises similaires ou concurrentes
Entreprise Prix de l'action Variation 1a% Pays
$100.56 -21.41%
US
$93.07 -2.95%
IE
$297.13 -23.49%
US
$44.47 -57.18%
US
$47.03 -17.91%
DE